Brainstorm Cell Therapeutics (NASDAQ: BCLI) is one of 185 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Brainstorm Cell Therapeutics to similar businesses based on the strength of its valuation, institutional ownership, risk, profitability, analyst recommendations, earnings and dividends.
Earnings and Valuation
This table compares Brainstorm Cell Therapeutics and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Brainstorm Cell Therapeutics||N/A||-$4.98 million||-9.97|
|Brainstorm Cell Therapeutics Competitors||$217.29 million||-$39.39 million||-63.86|
Brainstorm Cell Therapeutics’ peers have higher revenue, but lower earnings than Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings and recommmendations for Brainstorm Cell Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics||0||0||1||0||3.00|
|Brainstorm Cell Therapeutics Competitors||541||2379||6518||127||2.65|
Brainstorm Cell Therapeutics currently has a consensus price target of $9.00, suggesting a potential upside of 182.13%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.74%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Brainstorm Cell Therapeutics is more favorable than its peers.
Risk & Volatility
Brainstorm Cell Therapeutics has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics’ peers have a beta of 1.56, indicating that their average share price is 56% more volatile than the S&P 500.
This table compares Brainstorm Cell Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics||N/A||-76.45%||-59.84%|
|Brainstorm Cell Therapeutics Competitors||-4,482.97%||-468.10%||-42.48%|
Insider and Institutional Ownership
13.1% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 48.2% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 24.7% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Brainstorm Cell Therapeutics beats its peers on 9 of the 13 factors compared.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.